Cannabis is known for producing a diverse array of bioactive compounds, most notably tetrahydrocannabinol (THC) and cannabidiol (CBD). However, the evolutionary origins of these molecules have remained largely unclear—until now. Recent research has provided new insights into how these compounds developed and how they might be leveraged for future medical applications.

Tracing the Evolution of Cannabinoids

A team at Wageningen University & Research (WUR) in the Netherlands has mapped out how cannabis acquired the ability to synthesize THC, CBD, and another significant cannabinoid, cannabichromene (CBC). Their findings not only illuminate the plant’s evolutionary journey but also suggest new ways to utilize its chemical diversity.

In today’s cannabis strains, the levels of cannabinoids like THC, CBD, and CBC can vary greatly. These differences are primarily due to the activity of specific synthase enzymes, which have evolved over millions of years. The enzymes found in modern cannabis are highly specialized, quite distinct from those present in the plant’s ancient ancestors.

Reconstructing Ancient Enzymes

Using a technique called ancestral sequence reconstruction, the researchers recreated ancient cannabinoid-producing enzymes based on modern genetic information. When these enzymes were expressed in laboratory settings, the team could observe which cannabinoids they produced and how their functions compared to those of current enzymes.

The study revealed that, unlike the specialized enzymes of today, ancient versions were generalists. They could generate multiple cannabinoids—including THC, CBD, and CBC—from a single precursor molecule.

“What once seemed evolutionarily ‘unfinished’ turns out to be highly useful,” explained WUR researcher Robin van Velzen, who co-led the study with Cloé Villard. “These ancestral enzymes are more robust and flexible than their modern counterparts, making them promising candidates for new biotechnological and pharmaceutical applications.”

Unlocking the Potential of CBC

One of the most intriguing aspects of the research concerns CBC. While THC and CBD have been the primary focus of cannabis studies, CBC is emerging as a potentially valuable but underexplored cannabinoid. Modern cannabis plants typically contain less than 1% CBC, making it challenging to study and produce in significant quantities.

“At present, there is no cannabis plant with a naturally high CBC content,” noted van Velzen. “Introducing this enzyme into cannabis could pave the way for innovative medicinal strains.”

Preliminary research suggests that CBC may possess anti-inflammatory, anticonvulsant, and antibacterial properties, though its therapeutic potential is not as well understood as that of THC or CBD.

Biotechnological and Medical Implications

The team also discovered that these reconstructed ancestral enzymes are easier to produce in microorganisms, such as yeast, compared to their modern equivalents. This could enable more efficient synthesis of cannabinoids, including rare types, without the need for traditional plant cultivation—a development with significant implications for both research and pharmaceutical manufacturing.

By engineering hybrid enzymes based on these ancient forms, the researchers identified key amino acid changes that drove the evolution of cannabinoid-producing enzymes. These hybrid and ancestral enzymes not only exhibited unique activities but were also more amenable to production in laboratory settings.

Overall, this research enhances our understanding of the origins and molecular mechanisms behind cannabinoid synthesis. It opens up new possibilities for breeding, biotechnology, and the development of novel medicinal cannabis products.